2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody’s Ratings Agency Revises Outlook to Positive
PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
Revenue increased 9.0% to $451.1 million, compared to Q4 2021 Gross margin increased 3.5% to $128.8 million, compared to Q4...
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving...
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as...
INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving...
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating...
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address...
DENVER, March 16, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical...
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE...
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash,...
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the...
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data...
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16,...
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm...
WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
2022 total revenues of $26.5 million FDA approval of NexoBrid® in December 2022; U.S. commercial availability expected in the second...
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau),...
